MHRA approved Wegovy for a liver condition, its first non-weight, non-diabetes use
Awaiting primary-source check
On 3 July the MHRA approved semaglutide injection for the treatment of a form of liver disease, the first time the drug has been licensed in the UK for an indication outside weight management, type 2 diabetes and cardiovascular risk reduction.
What this actually means
This is a genuinely new use rather than a relabelling, and it matters beyond the people it directly affects.
Fatty liver disease is common, often silent, and has had almost no licensed drug treatment. For patients with it, a licensed option is a real change.
The wider point is about how these drugs are being understood. They started as diabetes treatments, became weight treatments, and are now picking up separate licences for separate organ effects. That does not mean they are good for everything. The EVOKE Alzheimer's trials failed, and most speculative uses will. It means each new use has to be proven on its own, one licence at a time, and this one was.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.